These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12610803)

  • 1. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease.
    Valleala H; Laasonen L; Koivula MK; Mandelin J; Friman C; Risteli J; Konttinen YT
    J Rheumatol; 2003 Mar; 30(3):468-73. PubMed ID: 12610803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis.
    Valleala H; Mandelin J; Laasonen L; Koivula MK; Risteli J; Konttinen YT
    Eur J Endocrinol; 2003 May; 148(5):527-30. PubMed ID: 12720535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women.
    Scariano JK; Glew RH; Bou-Serhal CE; Clemens JD; Garry PJ; Baumgartner RN
    Bone; 1998 Nov; 23(5):471-7. PubMed ID: 9823455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
    Garnero P; Thompson E; Woodworth T; Smolen JS
    Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
    Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross sectional study of bone and cartilage biomarkers: correlation with structural damage in rheumatoid arthritis.
    Ben Achour W; Bouaziz M; Mechri M; Zouari B; Bahlous A; Abdelmoula L; Laadhar L; Sellami M; Sahli H; Cheour E
    Libyan J Med; 2018 Dec; 13(1):1512330. PubMed ID: 30160204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
    Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K
    J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.
    Hakala M; Risteli J; Aman S; Kautiainen H; Korpela M; Hannonen P; Leirisalo-Repo M; Laasonen L; Paimela L; Möttönen T;
    Scand J Rheumatol; 2008; 37(2):90-3. PubMed ID: 18415764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density and serum levels of aminoterminal propeptides and cross-linked N-telopeptides of type I collagen in elderly men.
    Chandani AK; Scariano JK; Glew RH; Clemens JD; Garry PJ; Baumgartner RN
    Bone; 2000 May; 26(5):513-8. PubMed ID: 10773592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis.
    Wisłowska M; Jakubicz D; Stepień K; Cicha M
    Rheumatol Int; 2009 Oct; 29(12):1403-9. PubMed ID: 19219607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
    J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R; Thölix E
    Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
    Landewé R; Geusens P; Boers M; van der Heijde D; Lems W; te Koppele J; van der Linden S; Garnero P
    Arthritis Rheum; 2004 May; 50(5):1390-9. PubMed ID: 15146408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
    Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
    Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis.
    Hakala M; Aman S; Luukkainen R; Risteli L; Kauppi M; Nieminen P; Risteli J
    Ann Rheum Dis; 1995 Nov; 54(11):886-90. PubMed ID: 7492237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis.
    Sassi ML; Aman S; Hakala M; Luukkainen R; Risteli J
    Clin Chem Lab Med; 2003 Aug; 41(8):1038-44. PubMed ID: 12964811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis.
    Hasegawa J; Nagashima M; Yamamoto M; Nishijima T; Katsumata S; Yoshino S
    J Rheumatol; 2003 Mar; 30(3):474-9. PubMed ID: 12610804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.